Bullish Options Positioning in Hain Celestial (HAIN) with Shares Down 17% Today Following Q2 Earnings Miss -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Increasing unusual call option volume: EXP HAIN MGNX QNST LIVN SOXS IRBT CMG MHK HBI GRUB SONO MTCH
February 7, 2019 11:07 AM ESTIncreasing unusual call option volume: EXP HAIN MGNX QNST LIVN SOXS IRBT CMG MHK HBI GRUB SONO MTCH
... MorePre-Open Stock Movers 02/07: (IRBT) (LCI) (STI) Higher; (SLDB) (OSUR) (GRUB) Lower (more...)
February 7, 2019 9:27 AM ESTToday's Pre-Open Movers
Solid Biosciences (Nasdaq: SLDB) 72.8% LOWER; announced today preliminary findings from IGNITE DMD, the Companys Phase I/II dose-ascending clinical trial evaluating the safety and efficacy of SGT-001 microdystrophin gene transfer for the treatment of Duchenne muscular dystrophy (DMD). Initial three-month biopsy data showed low levels of microdystrophin protein expression. The Company is currently engaging with the appropriate parties to dose escalate as planned and as soon as possible.
Hain Celestial (HAIN) to Resume Trading at 8 am ET
February 7, 2019 7:44 AM ESTHain Celestial (NASDAQ: HAIN) to Resume Trading at 8 am ET
Hain Celestial (HAIN) Misses Q2 EPS by 12c, Guides FY EPS Well Below Consensus
February 7, 2019 7:32 AM ESTHain Celestial (NASDAQ: HAIN) reported Q2 EPS of $0.14, $0.12 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $584.2 million versus the consensus estimate of $613.15 million.
GUIDANCE:
Hain Celestial sees FY2019 EPS of $0.60-$0.70, versus the consensus of... More
Hain Celestial (HAIN) Halted, News Pending
February 7, 2019 7:25 AM ESTHain Celestial (NASDAQ: HAIN) Halted, News Pending
... More